Motif Bio Plc

NASDAQ: MTFBHealthcare / Biotechnology / United Kingdom
0.7800-0.0200-2.50%Vol 125 8501Y Perf -91.24%
Jun 20th, 2019 15:57
BID0.7500 ASK0.7800
Open0.7900 Previous Close0.8000
Pre-Market- After-Trading-
 - -%  - -%
Target Price
4.67 
Analyst Rating
Moderate Buy 2.33
Potencial %
498.72 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)12 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.65 
Earnings Date
9th Apr 2019

Today's Price Range

0.71000.7900

52wk Range

0.710011.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Month
-56.99%
3 Months
-68.00%
6 Months
-86.67%
1 Year
-91.24%
3 Years
-
5 Years
-

Name / TickerPriceChg.Chg.%
MTFB0.7800-0.0200-2.50
AAPL199.461.59000.80
GOOG1 111.429.09000.82
MSFT136.951.26000.93
XOM76.611.29001.71
WFC45.860.21000.46
JNJ142.211.76001.25
FB189.532.05001.09
GE10.630.29002.80
JPM110.190.28000.25
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2018 QR-0.450.00-
3/2019 QR-0.820.00-
12/2019 FY-1.208.40Positive
12/2020 FY-1.520.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume125 850
Shares Outstanding (in ths.)14 827
Trades Count171
Dollar Volume87 921
Avg. Volume438 830
Avg. Weekly Volume179 502
Avg. Monthly Volume136 181
Avg. Quarterly Volume161 933
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.33

Motif Bio Plc

Motif Bio PLC is a UK-based biopharmaceutical company. Its business is to develop antibiotics for the treatment of infections caused by multi-drug resistant bacteria. The company's key product is the Iclaprim, which addresses bacterial infections, such as acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia. Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. Motif Bio generates revenue from the sale of its pharmaceutical products mainly in the United Kingdom.

CEO: Graham George Lumsden

Teplephone: +1 609 608-0032

Address: 5 Independence Way, Princeton 08540, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

44%56%

Bearish Bullish

61%39%

News